Simulations Plus, Inc. (NASDAQ:SLP) has recently faced a downgrade from KeyBanc, shifting its stock rating from “Overweight” to “Sector Weight” without a specific price target. This decision was based on the ongoing challenges in the biopharma end market environment, which has a significant impact on Simulations Plus due to its customer concentration and exposure to the biotech industry. KeyBanc highlighted the expectation of weaker customer demand in the near-to-middle-term, reflecting the struggles faced by the company in the current market conditions.
In the third quarter of 2025, Simulations Plus saw a 10% increase in revenue compared to the previous quarter. This growth was driven by a 6% increase in software revenue, primarily attributed to the success of its ADMET Predictor® software along with modest growth in GastroPlus® and MonolixSuiteTM software. Additionally, services revenue experienced a significant uptick of 17%, largely due to the strong performance in Medical Communications services.
During the same period, the company underwent a strategic reorganization, transitioning from a business unit structure to a functionally driven operating model. This change marked the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies, and focusing resources on promising growth opportunities. Looking ahead to the full year of 2025, Simulations Plus anticipates revenue in the range of $76 million to $80 million.
In a recent investor letter, Wasatch Global Investors expressed confidence in Simulations Plus despite its recent struggles. The company has a track record of consistent growth and margin expansion, although concerns about the funding environment for biotechnology and pharmaceutical companies have impacted its stock performance. Wasatch Global Investors reduced its position in Simulations Plus due to worries related to the company’s acquisition strategy but remains optimistic about the growth potential of its core business.
Simulations Plus operates in the software industry, specializing in developing and producing software for pharmaceutical research and education. The company also offers consulting and contract research services to the broader pharmaceutical industry. While Simulations Plus shows promise as an investment, there are other AI stocks with greater upside potential and lower downside risk. For investors seeking undervalued AI stocks that could benefit from current economic trends, exploring alternative options may be worthwhile.
In conclusion, despite facing challenges in the market, Simulations Plus continues to evolve and adapt to meet the demands of the industry. With a focus on innovation and growth opportunities, the company remains a player to watch in the software and pharmaceutical sectors.
